


## PHARMACEUTICAL 2018

Bristol Myers Squibb

## BRISTOL MYERS SQUIBB CO Rank 182 of 342





## PHARMACEUTICAL 2018

Bristol Myers Squibb

## BRISTOL MYERS SQUIBB CO Rank 182 of 342

The relative strengths and weaknesses of BRISTOL MYERS SQUIBB CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BRISTOL MYERS SQUIBB CO compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 81% points. The greatest weakness of BRISTOL MYERS SQUIBB CO is the variable Assets, Current, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is 78%, being 32% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	14,854,000
Cost of Goods Sold	0
Intangible Assets	8,073,000
Liabilities, Current	9,563,000
Liabilities, Non-Current	8,139,000
Other Assets	5,623,000
Other Compr. Net Income	246,000
Other Expenses	8,703,000
Other Liabilities	4,002,000
Other Net Income	0
Other Revenues	20,776,000
Property and Equipment	5,001,000
Research and Development	6,411,000
Selling, General and Administrative Expense	4,687,000

Output Variable	Value in 1000 USD
Assets	33,551,000
Liabilities	21,704,000
Expenses	19,801,000
Revenues	20,776,000
Stockholders Equity	11,847,000
Net Income	975,000
Comprehensive Net Income	1,098,000
Economic Capital Ratio	78%

